The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family
Open accessAbstract
The interleukin (IL)-6/IL-12 family cytokines have pleiotropic functions and play critical roles in multiple immune responses. This cytokine family has very unique characteristics in that they are composed of two distinct subunits forming a heterodimer and each cytokine and receptor subunit shares with each other. The members of this cytokine family are increasing; currently, there are more than 6 cytokines, including the tentatively named cytokines IL-Y (p28/p40), IL-12 (p35/p40), IL-23 (p19/p40), IL-27 [p28/Epstein-Barr virus-induced protein 3 (EBI3)], IL-35 (p35/EBI3), and IL-39 (p19/EBI3). This family of cytokines covers a very broad range of immune responses, including pro-inflammatory responses such as helper T (Th)1, Th2, and Th17 to anti-inflammatory responses such as regulatory T (Treg) cells and IL-10-producing Treg cells. IL-12 is the first member of this family, and IL-12, IL-23, and IL-27 are mainly produced by activated antigen-presenting cells such as dendritic cells and macrophages. IL-12 plays a critical role in the promotion of Th1 immune responses by inducing interferon-γ production to combat pathogens and malignant tumors. IL-23 induces IL-17 production and is necessary to maintain pathogenic Th17 cells that cause inflammatory and autoimmune diseases. IL-27 was initially reported to play a critical role in promotion of Th1 differentiation; however, subsequent studies revealed that IL-27 has broader stimulatory and inhibitory roles by inducing IL-10-producing Treg cells. IL-35 is produced by forkhead box P3+ Treg cells and activated B cells and has immunosuppressive functions to maintain immune tolerance. The most recently identified cytokine, IL-39, is produced by activated B cells and has pro-inflammatory functions. The cytokine tentatively named IL-Y seems to have anti-inflammatory functions by inhibiting Th1 and Th17 differentiation. In addition, individual cytokine subunits were also shown to have self-standing activities. Thus, promiscuity within the IL-6/IL-12 family cytokines complicates structural and functional clarification and assignment of individual cytokines. A better understanding of the recent advances and expanding diversity in molecular structures and functions of the IL-6/IL-12 family cytokines could allow the creation of novel therapeutic strategies by using them as tools and targeted molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-6, which was discovered in 1986 (27), is a pleiotropic cytokine involved not only in immune responses but also in inflammation, hematopoiesis, bone metabolism, embryonic development and other fundamental processes (1, 21, 28–32).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature reviews. Immunology · doi:10.1038/nri1001 · Cited by 4,007
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K. P., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,819
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L., Workman, C., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R., & Vignali, D. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,152
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,665
Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M. A., Vaisberg, E., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00324-2 · Cited by 1,462
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,331
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., STERN, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Gazzinelli, R. T., Wysocka, M., Hieny, S. E., Scharton‐Kersten, T., Cheever, A. W., Kühn, R., Müller, W., Trinchieri, G., & Sher, A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.798 · Cited by 928
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 905
IL-35-mediated induction of a potent regulatory T cell population
Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P., Guy, C. S., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 870
Manz, M. G., & Boettcher, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3660 · Cited by 855
Awasthi, A., Carrier, Y., Peron, J. P. S., Bettelli, E., Kamanaka, M., Flavell, R. A., Kuchroo, V. K., Oukka, M., & Weiner, H. L. (2007) · Nature Immunology · doi:10.1038/ni1541 · Cited by 804
Polymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Interleukin-35 induces regulatory B cells that suppress autoimmune disease
Wang, R., Yu, C., Dambuza, I. M., Mahdi, R. M., Dolinska, M. B., Sergeev, Y. V., Wingfield, P. T., Kim, S.-H., & Egwuagu, C. E. (2014) · Nature Medicine · doi:10.1038/nm.3554 · Cited by 755
WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27
Pflanz, S., Hibbert, L., Mattson, J. D., Rosales, R., Vaisberg, E., Bazán, J. F., Phillips, J. H., McClanahan, T. K., Malefyt, R. D. W., & Kastelein, R. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2225 · Cited by 698
Polymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 686
Interleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose‐John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 532
The IL-27R (WSX-1) Is Required to Suppress T Cell Hyperactivity during Infection
Villarino, A. V., Hibbert, L., Lieberman, L. A., Wilson, E. H., Mak, T. W., Yoshida, H., Kastelein, R. A., Saris, C. J. M., & Hunter, C. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00300-5 · Cited by 484
The testis in immune privilege
Fijak, M., & Meinhardt, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00438.x · Cited by 483
The Immunobiology of Interleukin-27
Yoshida, H., & Hunter, C. A. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112134 · Cited by 472
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., García, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 465
Demand-adapted regulation of early hematopoiesis in infection and inflammation
Takizawa, H., Boettcher, S., & Manz, M. G. (2012) · Blood · doi:10.1182/blood-2011-12-380113 · Cited by 420
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller‐Newen, G., Grötzinger, J., Rose‐John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 409
IL-12p40: an inherently agonistic cytokine
Cooper, A. M., & Khader, S. A. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.11.002 · Cited by 343
Devergne, O., Hummel, M., Koeppen, H., Beau, M. M. L., Nathanson, E., Kieff, E. D., & Birkenbach, M. P. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1143-1153.1996 · Cited by 338
Interleukin-35 Limits Anti-Tumor Immunity
Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., Beres, A. J., Vogel, P., Workman, C. J., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.013 · Cited by 333
Interleukin-27: Balancing Protective and Pathological Immunity
Hunter, C. A., & KASTELEIN, R. A. (2012) · Immunity · doi:10.1016/j.immuni.2012.11.003 · Cited by 278
Hamano, S., Himeno, K., Miyazaki, Y., Ishii, K., Yamanaka, A., Takeda, A., Zhang, M., Hisaeda, H., Mak, T. W., Yoshimura, A., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00298-x · Cited by 264
Potent Antitumor Activity of Interleukin-27
Hisada, M., Kamiya, S., Fujita, K., Belladonna, M. L., Aoki, T., Koyanagi, Y., Mizuguchi, J., & Yoshimoto, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2084 · Cited by 246
Self-citationStructural, cellular and molecular aspects of immune privilege in the testis
Li, N., Wang, T., & Han, D. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00152 · Cited by 241
do Rosário, A. P. F., Lamb, T. J., Spence, P. J., Stephens, R., Lang, A., Roers, A., Müller, W., O’Garra, A., & Langhorne, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102755 · Cited by 210
A Role for IL-27 in Early Regulation of Th1 Differentiation
Owaki, T., Asakawa, M., Morishima, N., Hata, K., Fukai, F., Matsui, M., Mizuguchi, J., & Yoshimoto, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2191 · Cited by 207
Self-citationA role for IL-27p28 as an antagonist of gp130-mediated signaling
Stumhofer, J. S., Wojno, E. D. T., Quinn, W. J., Hosken, N. A., Spudy, B., Goenka, R., Fielding, C. A., O’Hara, A. C., Chen, Y., Jones, M. L., et al. (2010) · Nature Immunology · doi:10.1038/ni.1957 · Cited by 188
A novel IL‐23p19/Ebi3 (IL‐39) cytokine mediates inflammation in Lupus‐like mice
Wang, X., Wei, Y., He, X., Liu, X., Zhang, Y., Han, G., Chen, G., Hou, C., Ma, N., Shen, B., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546095 · Cited by 185
Pathogenesis of fibrosis: type 1 collagen and the skin
Trojanowska, M., LeRoy, E. C., Eckes, B., & Krieg, T. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050216 · Cited by 182
Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27
Pot, C., Apétoh, L., Awasthi, A., & Kuchroo, V. K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.003 · Cited by 175
Type 1 regulatory T cells (Tr1) in autoimmunity
Pot, C., Apetoh, L., & Kuchroo, V. K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.005 · Cited by 171
Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis
Wang, Z., Liu, J.-Q., Liu, Z., Shen, R. Z., Zhang, G., Xu, J., Basu, S., Feng, Y., & Bai, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202535 · Cited by 163
Crabé, S., Guay-Giroux, A., Tormo, A. J., Duluc, D., Lissilaa, R., Guilhot, F., Bigouagou, U. M., Lefouili, F., Cognet, I., Ferlin, W. G., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901464 · Cited by 138
Garbers, C., Spudy, B., Aparicio-Siegmund, S., Waetzig, G. H., Sommer, J., Hölscher, C., Rose‐John, S., Grötzinger, J., Lorenzen, I., & Scheller, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.432955 · Cited by 130
Lin, Q., Fang, D., Fang, J., Ren, X., Yang, X., Wen, F., & Su, S. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003007 · Cited by 124
Findlay, E. G., Greig, R., Stumhofer, J. S., Hafalla, J. C. R., de Souza, J. B., Saris, C. J. M., Hunter, C. A., Riley, E. M., & Couper, K. N. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904019 · Cited by 122
Owaki, T., Asakawa, M., Fukai, F., Mizuguchi, J., & Yoshimoto, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7579 · Cited by 121
Self-citationMultiple Stress Signals Activate Mutant p53 In Vivo
Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 119
Interleukin-27 directly induces differentiation in hematopoietic stem cells
Seita, J., Asakawa, M., Ooehara, J., Takayanagi, S., Morita, Y., Watanabe, N., Fujita, K., Kudo, M., Mizuguchi, J., Ema, H., et al. (2007) · Blood · doi:10.1182/blood-2007-06-093328 · Cited by 100
Self-citationWang, R., Yu, C., Mahdi, R. M., & Egwuagu, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.390625 · Cited by 95
Mitra, A., Satelli, A., Yan, J., Xueqing, X., Gagea, M., Hunter, C. A., Mishra, L., & Li, S. (2014) · Hepatology · doi:10.1002/hep.27392 · Cited by 94
Interleukin-27-Producing CD4+ T Cells Regulate Protective Immunity during Malaria Parasite Infection
Kimura, D., Miyakoda, M., Kimura, K., Honma, K., Hara, H., Yoshida, H., & Yui, K. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.011 · Cited by 87
Owaki, T., Asakawa, M., Morishima, N., Mizoguchi, I., Fukai, F., Takeda, K., Mizuguchi, J., & Yoshimoto, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2903 · Cited by 80
Self-citationZhang, S., Liang, R., Luo, W., Liu, C., Wu, X., Gao, Y., Hao, J., Cao, G., Chen, X., Wei, J., et al. (2012) · Hepatology · doi:10.1002/hep.26166 · Cited by 80
Furusawa, J.-I., Mizoguchi, I., Chiba, Y., Hisada, M., Kobayashi, F., Yoshida, H., Nakae, S., Tsuchida, A., Matsumoto, T., Ema, H., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005507 · Cited by 76
Self-citationNishino, R., Takano, A., Oshita, H., Ishikawa, N., Akiyama, H., Ito, H., Nakayama, H., Miyagi, Y., Tsuchiya, E., Kohno, N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0060 · Cited by 76
Defective production of and response to IL-2 in acute human falciparum malaria.
Ho, M., Webster, H. K., Green, B., Looareesuwan, S., Kongchareon, S., & White, N. J. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.8.2755 · Cited by 74
Wang, X., Liu, X., Zhang, Y., Wang, Z., Zhu, G., Han, G., Chen, G., Hou, C., Wang, T., Ma, N., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12840 · Cited by 66
Meo, S. D., Airoldi, I., Sorrentino, C., Zorzoli, A., Esposito, S., & Carlo, E. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2240 · Cited by 61
Villegas-Méndez, A., de Souza, J. B., Lavelle, S.-W., Findlay, E. G., Shaw, T. N., van Rooijen, N., Saris, C. J. M., Hunter, C. A., Riley, E. M., & Couper, K. N. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003293 · Cited by 57
TLR3 drives IRF6‐dependent IL‐23p19 expression and p19/EBI3 heterodimer formation in keratinocytes
Ramnath, D., Tunny, K. A., Hohenhaus, D. M., Pitts, C. M., Bergot, A., Hogarth, P. M., Hamilton, J. A., Kapétanovic, R., Sturm, R. A., Scholz, G. M., et al. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2015.77 · Cited by 57
Potential clinical application of interleukin‐27 as an antitumor agent
Yoshimoto, T., Chiba, Y., Furusawa, J.-I., Xu, M., Tsunoda, R., Higuchi, K., & Mizoguchi, I. (2015) · Cancer Science · doi:10.1111/cas.12731 · Cited by 54
Self-citationDibra, D., Cutrera, J. J., Xia, X., Kallakury, B., Mishra, L., & Li, S. (2011) · Hepatology · doi:10.1002/hep.24814 · Cited by 52
Espígol‐Frigolé, G., Planas‐Rigol, E., Ohnuki, H., Salvucci, O., Kwak, H., Ravichandran, S., Luke, B. T., Cid, M. C., & Tosato, G. (2016) · Science Signaling · doi:10.1126/scisignal.aad2357 · Cited by 48
A Soluble Form of IL-27Rα Is a Natural IL-27 Antagonist
Dietrich, C., Candon, S., Ruemmele, F. M., & Devergne, O. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303435 · Cited by 37
Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells
Yan, J., Mitra, A., Hu, J., Cutrera, J. J., Xia, X., Doetschman, T., Gagea, M., Mishra, L., & Li, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.020 · Cited by 36
Tormo, A., Meliani, Y., Beaupré, L., Sharma, M., Fritz, J. H., Elson, G., Crabé, S., & Gauchat, J. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1201595 · Cited by 34
Franke, M., Schröder, J., Monhasery, N., Ackfeld, T., Hummel, T. M., Rabe, B., Garbers, C., Becker‐Pauly, C., Floss, D. M., & Scheller, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710541 · Cited by 33
Flores, R. R., Kim, E. Y., Zhou, L., Yang, C., Zhao, J., Gambotto, A. A., & Robbins, P. D. (2015) · European Journal of Immunology · doi:10.1002/eji.201445403 · Cited by 32
Li, M.-F., Sun, B.-G., Xiao, Z., & Sun, L. (2013) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2013.07.022 · Cited by 31
Dibra, D., Xia, X., Mitra, A., Cutrera, J., Lozano, G., & Li, S.-L. (2016) · Hepatology · doi:10.1002/hep.28379 · Cited by 30
EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin
Kudo, H., Wang, Z., Jinnin, M., Nakayama, W., Inoue, K., Honda, N., Nakashima, T., Kajihara, I., Makino, K., Makino, T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402362 · Cited by 30
Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35
Aparicio-Siegmund, S., Moll, J. M., Lokau, J., Grusdat, M., Schröder, J., Philipp, S., Rose‐John, S., Grötzinger, J., Lang, P. A., Scheller, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107990 · Cited by 30
Contribution of IL-12/IL-35 Common Subunit p35 to Maintaining the Testicular Immune Privilege
Terayama, H., Yoshimoto, T., Hirai, S., Naito, M., Qu, N., Hatayama, N., Hayashi, S., Mitobe, K., Furusawa, J.-I., Mizoguchi, I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096120 · Cited by 28
Self-citationBioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents
Belladonna, M. L., & Grohmann, U. (2013) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2013.801228 · Cited by 25
Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Dibra, D., Mitra, A., Newman, M., Xia, X., Cutrera, J. J., Gagea, M., Kleinerman, E. S., Lozano, G., & Li, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2052 · Cited by 18
Tormo, A. J., Letellier, M.-C., Lissilaa, R., Batraville, L.-A., Sharma, M., Ferlin, W. G., Elson, G., Crabé, S., & Gauchat, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.014 · Cited by 17
Therapeutic potential of interleukin-27 against cancers in preclinical mouse models
Mizoguchi, I., Chiba, Y., Furusawa, J.-I., Xu, M., Tsunoda, R., Higuchi, K., & Yoshimoto, T. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1042200 · Cited by 5
Self-citation
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“IL-6, which was discovered in 1986 (27), is a pleiotropic cytokine involved not only in immune responses but also in inflammation, hematopoiesis, bone metabolism, embryonic development and other fundamental processes (1, 21, 28–32).”
BackgroundThe cytokine network involved in the host immune response to periodontitis
Pan, W., Wang, Q., & Chen, Q. (2019) · International Journal of Oral Science · doi:10.1038/s41368-019-0064-z · Cited by 740
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533
Historical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva‐Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 307
Metadata
- Authors
- Hasegawa, H., Mizoguchi, I., Chiba, Y., Ohashi, M., Xu, M., & Yoshimoto, T.
- Affiliations
- Tokyo Medical University (JP)
- Corresponding author
- Yoshimoto, Takayuki
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2016-11-04
- Volume
- 7
- Pages
- 479-479
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5095122
- OpenAlex
- W2548333195
- Cited by
- 142
- References
- 79
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 16 · 2023: 14 · 2022: 13 · 2021: 16 · 2020: 16 · 2019: 17 · 2018: 22 · 2017: 9
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (16J04160, 15K07947, 15K08433)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- heterodimeric cytokine, IL-12, IL-23, IL-27, IL-35, IL-39, p40 subunit, EBI3, Th1 cells, Th17 cells, regulatory T cells, IL-10, interferon-gamma, IL-17, dendritic cells, macrophages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review